Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Excess visceral adiposity is strongly associated with: Type 2 diabetes mellitus and insulin resistance Cardiovascular disease and hypertension Non-alcoholic fatty liver disease (NAFLD) Certain cancers, including colorectal and breast cancer Metabolic syndrome According to NHS guidance, waist circumference measurements exceeding 94 cm in men and 80 cm in women (for white European populations) indicate increased metabolic risk, largely driven by visceral fat accumulation
Hypoglycemia : The risk of low blood sugar may increase when using compounded tirzepatide alongside other blood-sugar-lowering medications
L.JamialahmadiT.SahebkarA
past advisory board of Eli Lilly
